Biofabrication of a tri-layered 3D-bioprinted CSC-based malignant melanoma model for personalized cancer treatment

Biofabrication. 2023 May 15;15(3). doi: 10.1088/1758-5090/ac8dc6.

Abstract

Conventionalin vitrocancer models do not accurately reproduce the tumor microenvironment (TME), so three-dimensional (3D)-bioprinting represents an excellent tool to overcome their limitations. Here, two multicellular tri-layered malignant melanoma (MM) models composed by cancer stem cells (CSCs) isolated from a MM established cell line or a primary-patient derived cell line, fibroblasts, mesenchymal stem cells, and endothelial cells, embedded within an agarose-collagen type I hydrogel were bioprinted. Embedded-cells showed high proliferation and metabolic activity, and actively remodeled their TME. MM hydrogels displayed similar rheological properties that skin and were able to support an early onset of vascularization. Besides, MM hydrogels displayed different response to vemurafenib compared with cell cultures, and supported tumorigenesis in murine xenotransplant achieving more mimeticin vivomodels. For the first time a tri-layered 3D-bioprinted CSC-based human MM model is developed recreating TMEin vitroandin vivoand response to treatment, being useful for precision treatment regimens against MM.

Keywords: 3D bioprinting; malignant melanoma; melanoma 3D model; tumor microenvironment; tumor model.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Bioprinting* / methods
  • Collagen Type I / metabolism
  • Endothelial Cells
  • Humans
  • Hydrogels / pharmacology
  • Melanoma* / drug therapy
  • Melanoma* / metabolism
  • Mesenchymal Stem Cells*
  • Mice
  • Printing, Three-Dimensional
  • Tissue Engineering / methods
  • Tumor Microenvironment

Substances

  • Hydrogels
  • Collagen Type I